| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3192052 | Annals of Allergy, Asthma & Immunology | 2010 | 6 Pages |
Abstract
The addition of omalizumab to baseline therapy in patients 12 years or older with moderate to severe persistent allergic asthma resulted in a durable reduction in the overall steroid burden and improvement in other clinical measures of asthma control.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Jill MD, Marc PharmD, Gregory P. MD, MPH, Farid PhD, Neil MD, Robert K. MD,